Ignacio Garrido-Laguna: Dosing first patient in the world with BBO-11818, a novel PanKras inhibitor
Ignacio Garrido-Laguna, Director of Phase 1 Program at Huntsman Cancer Institute, reshared a post by BridgeBio Oncology Therapeutics (BBOT) on LinkedIn, adding:
“Dosing first patient in the world with BBO-11818, a novel PanKras inhibitor is a great opportunity to acknowledge team work.
Very grateful to our patient for trusting us with his care at a very difficult time in life. Grateful for giving us his precious time to participate in this important research.
Grateful for a terrific Clinical Trials Office team at Huntsman Cancer Institute that understands priorities and works expeditiously and with a sense of urgency to bring novel treatments to our patients. Everyone from our finance, regulatory, contract, IDS teams working like a perfectly oiled machine. You all make a difference everyday. I am so proud of you. The priorities are very clear. The time is now. Patients come to us asking for new treatments. Their need is immediate. We see that every day. The most important thing we do at a cancer center is to take care of patients with cancer. Focus should be on our patients and translational research a priority. Centers and leaders that don’t understand this will fall behind.
Thanks Heloisa S. for amazing leadership at CTO. Thanks to my colleagues who lead trial accrual Neeraj Agarwal, Umang Swami and many others who every day work tirelessly for our patients and show clinical research matters.
Finally thanks to BridgeBio Oncology Therapeutics (BBOT) for conducting novel research to bring BBO-11818 to the clinic. Pedro J. Beltran Rohan Shah and Danielle McMullin, RN and many others behind scene.”
Quoting BridgeBio Oncology Therapeutics (BBOT)‘s post:
“Today, we announced the first patient has been dosed with BBO-11818 in the KONQUER-101 trial for patients with advanced solid tumors, marking our third program to enter the clinic.
BBO-11818 is an orally bioavailable small molecule panKRAS dual inhibitor that directly binds to both the “ON” and “OFF” states of KRAS and has the potential to provide significant benefit to patients with tumors by safely achieving optimal target inhibition.
Read more about the news here.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023